FindTrial
Sign In

Establishment and popularization of the standardized pathological diagnosis path about thick needle biopsy specimens of lymphoma

Establishment and popularization of the standardized pathological diagnosis path about thick needle biopsy specimens of lymphoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036289
Enrollment
Unknown
Registered
2020-08-22
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma

Interventions

Gold Standard:Pathological diagnosis for surgically resected specimens.
Index test:thick&#32
needle&#32
biopsy&#32
specimens

Sponsors

Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Outpatients and inpatients; 2. There is no restriction on gender and age; 3. Basic conditions can tolerate invasive inspection operations; 4. Clinical consideration of lymphoid hematopoietic system diseases, and is a newly treated patient; 5. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Bleeding diseases; 2. The basic situation cannot tolerate invasive inspection operations; 3. Have a history of lymphoma and have received treatment; 4. There is a history of other malignant tumors, and it is clinically considered as lymph node metastasis.

Design outcomes

Primary

MeasureTime frame
Immunohistochemistry;SEN, SPE, ACC, AUC of ROC;—

Secondary

MeasureTime frame
Fluorescence In Situ Hybridization;High-throughput sequencing;—

Countries

China

Contacts

Public ContactWang Chaofu

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

wangchaofu@126.com+86 18917762922

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026